Brain Tumor Drugs Market Report 2023

Brain Tumor Drugs Global Market Report 2023 – By Type (Medulloblastoma, Astrocytoma, Oligodendroglioma, Primitive Neuroectodermal (PNET), Others (Glioma, Acoustic Neuroma, Meningioma), By Drugs (Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib), By End User (Hospital Pharmacies, Clinics, Other EndUsers) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : January 2023 | Delivery Time: 2-3 business days | Format :

Need assistance or more information before the purchase?

Enquire Before Buying
Infoimg

Proud Members Of

Brain tumor drugs refer to the drugs or medications that are used to treat brain tumor. Chemotherapy, hormone therapies, anticonvulsants, and painkillers are among the drugs used to treat brain tumours. While other prescription drugs are used to manage symptoms while the tumour is being treated, chemotherapy works to reduce or destroy brain tumours.

The main types of drugs in brain tumors drugs are temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide is a drug that is intended to treat some types of brain cancer (e.g., glioblastomamultiforme, anaplastic astrocytoma) in individuals who have had tumours return or who have recently been diagnosed with tumours. It’s one of a class of drugs called antineoplastics (cancer medicines). The different types include medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others (glioma, acoustic neuroma, meningioma) and are used in various sectors such as hospital pharmacies, clinics, and others.

The brain tumor drugs market research report is one of a series of new reports from The Business Research Company that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global brain tumor drugs market size will grow from $3.49 billion in 2022 to $3.74 billion in 2023 at a compound annual growth rate (CAGR) of 7.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global brain tumor drugs market size is expected to grow to $4.74 billion in 2027 at a CAGR of 6.1%.

The major driving factor responsible for the growth of the Brain Tumor market is the increasing prevalence of Neurological Disorders, worldwide. Neurological Disorders are identified as one of the most prevalent disorders, due to longer life expectancy, increasing exposure to infections, and sedentary lifestyles. For example, as per the National Brain Tumor Society, around 700,000 people in the United States around 700,00 people are having a primary brain tumor, and around 86,000 more will be diagnosed. The increasing number of patients with neurological disorders including brain tumor is leading to a rise in the demand for the drugs used in their treatment.

The increasing use of targeted therapies is acting as a restraint on the Brain Tumor drug market. Targeted cancer therapies are drugs or substances which block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of targeted cancer therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. For example, Everolimus is a targeted therapy that especially blocks cancer cells from growing and spreading. Similarly, Bevacizumab prevents the regeneration of cancer cells, unlike chemical drugs which cannot prevent regeneration. This rising popularity of targeted therapies is expected to affect the sales of conventional chemical Brain Tumor drugs, thus restraining the growth of the market during the forecast period.

Companies in the brain tumor market are focusing on the use of nanotechnology for treatment. The nanoparticles are being used to carry drugs in combination, directly to the cancer cells or into the tumor. This technology has also led to a reduction in the dosage of the drugs, improved shelf life, and reduced toxicity. A few nanodrugs are proving to be useful in overcoming the blood-brain barrier, which was a significant challenge in the treatment of Brain tumors. For instance, Liposomes nanoparticles facilitate easy delivery of drugs to the core cancer cells, these particles if coated with transferrin can even pass through the blood-brain barrier. Companies including GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are adopting this technology to improve the available techniques of medication and treatment.

The brain tumor market is governed by regulatory authorities such as the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The regulatory body requires the companies in the industry to adhere to the same rules for conducting clinical trials, consistently throughout the region. These rules are relating to the transparency of information and maintaining safety standards while conducting clinical trials of newly discovered drugs and therapies throughout the EU. The regulation also encourages cross-border cooperation for making the scope of these clinical tests wider.

In December 2021, Sanofi, a France-based pharmaceutical company acquired Amunix Pharmaceuticals Inc. for a deal amount of $1 billion. Through this acquisition, Sanofi’s focus is on developing potentially transformative cancer therapies in immuno-oncology. Amunix Pharmaceuticals Inc. is a US-based pharmaceutical company that also includes brain tumor drugs.

Major players in the brain tumor drugs market are Pfizer Inc., Shimadzu Corporation, Toshiba Medical Systems, Merck & Co. Inc., AstraZeneca, Carestream Health, Philips Healthcare, Siemens Healthineers, Hitachi Medical Corporation and GE Healthcare.

North America was the largest region in the brain tumor drugs market in 2022. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market during the forecast period. The regions covered in the global brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The global brain tumor drugs market is segmented -

1) By Type: Medulloblastoma, Astrocytoma, Oligodendroglioma, Primitive Neuroectodermal (PNET), Others (Glioma, Acoustic Neuroma, Meningioma)

2) By Drugs: Temozolomide, Carmustine, Cisplatin, Bevacizumab, Geftinib, Erlotinib

3) By End User: Hospital Pharmacies, Clinics, Other End-Users

    Table Of Contents

    1. Executive Summary

    2. Brain Tumor Drugs Market Characteristics

    3. Brain Tumor Drugs Market Trends And Strategies

    4. Brain Tumor Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Brain Tumor Drugs Market

    4.2 Ukraine-Russia War Impact On Brain Tumor Drugs Market

    4.3 Impact Of High Inflation On Brain Tumor Drugs Market

    5. Brain Tumor Drugs Market Size And Growth

    5.1. Global Brain Tumor Drugs Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Brain Tumor Drugs Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Brain Tumor Drugs Market Segmentation

    6.1. Global Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Medulloblastoma

    Astrocytoma

    Oligodendroglioma

    Primitive Neuroectodermal (PNET)

    Other Types (Glioma, Acoustic Neuroma, Meningioma)

    6.2. Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Temozolomide

    Carmustine

    Cisplatin

    Bevacizumab

    Geftinib

    Erlotinib

    6.3. Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacies

    Clinics

    Other End User

    7. Brain Tumor Drugs Market Regional And Country Analysis

    7.1. Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Brain Tumor Drugs Market

    8.1. Asia-Pacific Brain Tumor Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Brain Tumor Drugs Market

    9.1. China Brain Tumor Drugs Market Overview

    9.2. China Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Brain Tumor Drugs Market

    10.1. India Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Brain Tumor Drugs Market

    11.1. Japan Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Brain Tumor Drugs Market

    12.1. Australia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Brain Tumor Drugs Market

    13.1. Indonesia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Brain Tumor Drugs Market

    14.1. South Korea Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Brain Tumor Drugs Market

    15.1. Western Europe Brain Tumor Drugs Market Overview

    15.2. Western Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Brain Tumor Drugs Market

    16.1. UK Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Brain Tumor Drugs Market

    17.1. Germany Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Brain Tumor Drugs Market

    18.4. France Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Brain Tumor Drugs Market

    19.1. Eastern Europe Brain Tumor Drugs Market Overview

    19.2. Eastern Europe Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Brain Tumor Drugs Market

    20.1. Russia Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Brain Tumor Drugs Market

    21.1. North America Brain Tumor Drugs Market Overview

    21.2. North America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Brain Tumor Drugs Market

    22.1. USA Brain Tumor Drugs Market Overview

    22.2. USA Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Brain Tumor Drugs Market

    23.1. South America Brain Tumor Drugs Market Overview

    23.2. South America Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Brain Tumor Drugs Market

    24.1. Brazil Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Brain Tumor Drugs Market

    25.1. Middle East Brain Tumor Drugs Market Overview

    25.2. Middle East Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Brain Tumor Drugs Market

    26.1. Africa Brain Tumor Drugs Market Overview

    26.2. Africa Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Brain Tumor Drugs Market Competitive Landscape And Company Profiles

    27.1. Brain Tumor Drugs Market Competitive Landscape

    27.2. Brain Tumor Drugs Market Company Profiles

    27.2.1. Pfizer Inc.

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Shimadzu Corporation

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Toshiba Medical Systems

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Merck & Co. Inc.

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. AstraZeneca

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Brain Tumor Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Brain Tumor Drugs Market

    30. Brain Tumor Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Pfizer Inc. Financial Performance
  • Table 47: Shimadzu Corporation Financial Performance
  • Table 48: Toshiba Medical Systems Financial Performance
  • Table 49: Merck & Co. Inc. Financial Performance
  • Table 50: AstraZeneca Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Brain Tumor Drugs Market, Segmentation By Drugs, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Brain Tumor Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Brain Tumor Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Brain Tumor Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Brain Tumor Drugs Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Pfizer Inc. Financial Performance
  • Figure 47: Shimadzu Corporation Financial Performance
  • Figure 48: Toshiba Medical Systems Financial Performance
  • Figure 49: Merck & Co. Inc. Financial Performance
  • Figure 50: AstraZeneca Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report